Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 27 2023 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
members of the Aclaris management team will participate in a
fireside chat during the H.C. Wainwright Autoimmune &
Inflammatory Disease Virtual Conference on Thursday, March 30, 2023
at 1:00 PM ET.
A webcast of the fireside chat may be accessed through the
“Events” page of the “Investors” section of Aclaris’ website,
www.aclaristx.com. The webcast will be archived for at least 30
days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Aclaris Therapeutics Contact:
Robert A. Doody Jr.Vice President, Investor
Relations484-639-7235rdoody@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024